Literature DB >> 27517975

Evaluation of CD4+ CD25+/- CD39+ T-cell populations in peripheral blood of patients following kidney transplantation and during acute allograft rejection.

Jennifer L McRae1, Joanne Sj Chia1, Sandra A Pommey1, Karen M Dwyer1,2,3.   

Abstract

AIM: Regulatory T cells (Treg) are important in mediating immune tolerance and outcomes of allotransplantation. CD4+ CD25+ CD39+ co-expression identifies memory Treg; CD4+ CD25- CD39+ memory T effectors. We sought to determine CD4+ CD25+/- CD39+ expression from the peripheral blood of patients with end stage renal failure, following transplantation and during episodes of acute cellular rejection.
METHODS: CD4+ T cells were isolated from peripheral blood leucocytes and analysed for CD25 and CD39 expression by flow cytometry. Treg suppressive function was measured by suppression of autologous effector T-cell proliferation by Treg in co-culture.
RESULTS: CD4+ CD25+/- CD39+ T-cell subsets were tracked longitudinally in the peripheral blood of 17 patients following renal transplantation. Patients with acute T-cell-mediated rejection diagnosed on biopsy had reduced CD4+ CD25+ CD39+ mTreg (P < 0.05) and CD4+ CD25- CD39+ mTeff (P < 0.01) cells compared with non-rejecting patients. CD4+ CD25+ CD39+ mTreg (P < 0.05) and CD4+ CD25- CD39+ mTeff (P = 0.057) were reduced in long-term transplant patients (>1 year) compared with non-immunosuppressed controls. Interestingly, remaining CD4+ CD25+ CD39+ mTreg in the stable transplant patients displayed more potent suppressive capacity compared with non-immunosuppressed controls (83.2% ± 3.1% vs 45.7% ± 8.0%, nTeff:Treg ratio 8:1, P < 0.01).
CONCLUSION: CD4+ CD25+ CD39+ mTreg and CD4+ CD25- CD39+ mTeff in peripheral blood can be tracked in renal transplant patients. Acute cellular rejection was accompanied by reduced mTreg and mTeff. Determining changes in these T-cell subsets may help to identify patients with, or at high risk of, renal allograft rejection.
© 2016 Asian Pacific Society of Nephrology.

Entities:  

Keywords:  CD39; Treg; acute cellular rejection; kidney; renal transplantation

Mesh:

Substances:

Year:  2017        PMID: 27517975     DOI: 10.1111/nep.12894

Source DB:  PubMed          Journal:  Nephrology (Carlton)        ISSN: 1320-5358            Impact factor:   2.506


  5 in total

Review 1.  CD39-adenosinergic axis in renal pathophysiology and therapeutics.

Authors:  Bellamkonda K Kishore; Simon C Robson; Karen M Dwyer
Journal:  Purinergic Signal       Date:  2018-01-13       Impact factor: 3.765

Review 2.  Regulation of the Immune Response by the Inflammatory Metabolic Microenvironment in the Context of Allotransplantation.

Authors:  Nicolas Degauque; Carole Brosseau; Sophie Brouard
Journal:  Front Immunol       Date:  2018-06-25       Impact factor: 7.561

3.  Immunoregulation induced by autologous serum collected after acute exercise in obese men: a randomized cross-over trial.

Authors:  Gilson P Dorneles; Igor M da Silva; Maeli Andressa Santos; Viviane R Elsner; Simone G Fonseca; Alessandra Peres; Pedro R T Romão
Journal:  Sci Rep       Date:  2020-12-10       Impact factor: 4.379

4.  Use of Tregs as a cell-based therapy via CD39 for benign prostate hyperplasia with inflammation.

Authors:  Xi Jin; Tianhai Lin; Guang Yang; Huawei Cai; Bo Tang; Xinyang Liao; Huifang Li; Xiaoting Chen; Lina Gong; Hang Xu; Yi Sun; Ping Tan; Jianqiong Yin; Hongwen Ma; Jianzhong Ai; Kunjie Wang; Qiang Wei; Lu Yang; Hong Li
Journal:  J Cell Mol Med       Date:  2020-03-19       Impact factor: 5.310

5.  Everolimus-Induced Immune Effects after Heart Transplantation: A Possible Tool for Clinicians to Monitor Patients at Risk for Transplant Rejection.

Authors:  Kristin Klaeske; Sven Lehmann; Robert Palitzsch; Petra Büttner; Markus J Barten; Khalil Jawad; Sandra Eifert; Diyar Saeed; Michael A Borger; Maja-Theresa Dieterlen
Journal:  Life (Basel)       Date:  2021-12-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.